RBC Capital Markets Maintains Outperform Rating for Smith & Nephew plc - Depositary Receipt (SNN)
Analyst Recommendation: RBC Capital Markets has reiterated an "Outperform" rating for Smith & Nephew plc - Depositary Receipt (NYSE:SNN), with an average one-year price target of $38.14/share, indicating a potential upside of 4.34% from its current price of $36.55/share.
Fund Sentiment: There are 281 funds reporting positions in Smith & Nephew, with a 2.55% increase in ownership over the last quarter. The average portfolio weight for these funds has risen by 8.83%.
Institutional Holdings: Notable changes in institutional holdings include Bank Of Montreal increasing its shares by 76.28%, while Goldman Sachs Group decreased its portfolio allocation by 71.85%.
Market Outlook: The put/call ratio for SNN is 0.23, suggesting a bullish sentiment among investors, despite a projected annual revenue decrease of 3.55% to $5,733MM.
Trade with 70% Backtested Accuracy
Analyst Views on SNN
About SNN
About the author


- Acquisition Integration: Smith+Nephew has completed the acquisition of US-based Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business by offering the most comprehensive suite of rotator cuff repair technologies available, which is expected to significantly enhance market competitiveness.
- Innovative Technology: The Tendon Seam™ system from Integrity Orthopaedics features a unique repair stitch configuration and patented microanchors designed to reduce re-tear rates and improve patient outcomes, with early clinical data indicating lower re-tear rates and faster recovery compared to traditional methods.
- Market Potential: With approximately 500,000 rotator cuff repair procedures performed annually in the US, and traditional techniques suffering from structural failure rates of 20-40%, the introduction of Tendon Seam™ is poised to change this landscape, enhancing surgical success rates and patient satisfaction.
- Global Promotion Plan: Smith+Nephew plans to leverage its commercial channels in the US to accelerate the adoption of Tendon Seam™, while building a base of evidence to support global adoption, further solidifying its leadership position in the biomechanical repair sector.
- Rating Downgrade: Goldman Sachs analyst Katherine Murphy initiated coverage of Super Micro Computer (NASDAQ:SMCI) on January 13 with a Sell rating and a price target of $26, reflecting a pessimistic outlook that may lead to decreased investor confidence.
- Merger Approval: Shareholders of Huntington Bancshares (NASDAQ:HBAN) and Cadence Bank approved their pending merger on January 6, which is expected to enhance market competitiveness and resource integration, driving future business growth.
- Analyst Support: Multiple analysts initiated coverage of Medline Inc. (NASDAQ:MDLN) on January 12 with bullish ratings, indicating a positive market sentiment towards the company's prospects that could attract more investor interest.
- Market Reaction: Super Micro Computer's shares jumped 11.1% to settle at $32.66 on Friday, indicating mixed market reactions to Jim Cramer's sell recommendation, which may influence subsequent investment decisions.

- Acquisition Overview: Smith & Nephew acquires Integrity Orthopaedics for $225 million, with an additional $225 million tied to performance milestones over five years, expected to enhance group trading profit margins by 2028, reflecting confidence in commercial execution and operational leverage.
- Market Potential: Approximately 500,000 rotator cuff repair procedures are performed annually in the U.S., representing an estimated $875 million market opportunity, with traditional techniques facing 20%-40% structural failure rates; Integrity Orthopaedics' Tendon Seam system aims to reduce re-tear rates through patented micro-anchors and continuous suturing, improving patient outcomes.
- Portfolio Integration: The Tendon Seam system complements Smith & Nephew's existing shoulder solutions, enhancing its market position across biological augmentation, mechanical repair, and joint replacement, further solidifying its role as a full-spectrum shoulder solutions provider.
- Long-term Strategic Impact: The acquisition is expected to close before the end of January 2026, leading investors to view it as a long-term growth enabler rather than a near-term financial stretch, supporting the company's share expansion in the fast-growing rotator cuff repair market.
- Super Micro Computer Rating: Analysts have rated Super Micro Computer as a sell, indicating concerns about its future performance, which could lead to decreased investor confidence and negatively impact its stock price.
- Alkermes Stock Recommendation: Alkermes has been rated as not recommended by analysts, reflecting skepticism about its growth potential, which may affect its ability to raise capital and overall market performance.
- Medline Investment Outlook: Medline is strongly recommended as a buy by analysts, who describe its stock performance as 'unbelievable', potentially attracting more investor interest and driving its stock price higher.
- STMicroelectronics Investment Advice: STMicroelectronics is viewed as cheap and performing well, with analysts suggesting a buy, which could attract value investors and enhance its market position.
- Market Size Analysis: The wrist replacement market is expected to expand significantly by 2036, driven by the increasing number of arthritis patients and wrist fractures due to the aging global population.
- Product Segmentation: The report covers Total Wrist Replacement and Ulnar Head Replacement, providing detailed data on market share, average selling prices, and intervention volumes, aiding companies in formulating precise market strategies.
- Competitive Landscape Insights: The analysis of major players like Stryker and Smith & Nephew includes SWOT analysis, helping investors identify potential investment targets and market opportunities.
- Policy and Regulatory Environment: The report delves into the healthcare systems, reimbursement policies, and regulatory landscapes of various countries, supporting companies in strategic planning to maintain competitiveness in complex markets.
- Acquisition Agreement: Sintana and the Independent Challenger Directors have reached an agreement for Sintana to acquire all ordinary shares of Challenger, indicating a proactive strategy for business expansion and asset consolidation.
- Shareholder Voting Results: At the General Meeting on November 26, 2025, over 75% of Scheme Shareholders voted in favor of the scheme, reflecting strong investor confidence in the acquisition, which is expected to enhance Sintana's market position.
- Clear Next Steps: The acquisition completion is still subject to court approval, anticipated to become effective on December 11, 2025, ensuring Sintana's strategic flexibility in future business integration and resource allocation.
- Market Reaction Anticipated: Sintana plans to seek AIM listing post-acquisition, which is expected to enhance its visibility in capital markets and financing capabilities, thereby supporting future expansion and investment initiatives.








